Avalyn's upsized IPO; Alector ends another study in GSK partnership
🔔 Avalyn Pharma’s $300M IPO: The Boston, MA-based biotech is selling over 16.5 million shares at $18 apiece. The company is set to start trading as {$AVLN} on the Nasdaq Thursday ...
Read the full article on the original site.
Read Full Article